Earnings Releases·Oct 27, 2026, 7:40 AM ET

Zura Bio — Third Quarter 2026 Earnings Summary

Cash and cash equivalents increased to $187.7 million as of September 30, 2026, from $109.4 million at year-end 2025, providing a runway to fund operations through at least the end of 2028.
Net loss widened to $25.8 million ($0.20 per share) for the quarter ended September 30, 2026, compared to $18.0 million ($0.21 per share) in the prior year period, driven by a 48% increase in total operating expenses to $28.8 million.
Clinical development remains on track with top-line data expected for the TibuSHIELD study in Q4 2026 and the TibuSURE study in H1 2027, while the NEXUS-PMR Phase 2 study is scheduled to initiate by year-end 2026.
The company completed enrollment for both TibuSHIELD (247 participants) and TibuSURE (91 participants) Phase 2 studies, exceeding targets, and noted the FDA clearance to proceed with the NEXUS-PMR study under an Investigational New Drug application.